(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Share This 
Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This 
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This 
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
Share This 
BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
Share This 
78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Share This Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This 
3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
Share This 
As therapeutic drugs have grown in complexity, so too have the bioanalysis techniques to support these products. Bioanalysis of small molecule
Share This 
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Chad Briscoe speaks with Dr. David Berkowitz, Director of the Division of Chemistry at
Share This Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
Share This Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With
Share This BioAgilytix adds New VP of Business Development in Europe Hamburg, Germany 01 March 2023 – BioAgilytix, a leading global bioanalytical
Share This 78,000 Square Feet of Lab and Office Space Added in the First of a Multi-Phase Expansion Durham, NC, October 19,
Share This Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing
Share This 3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a
Share This As therapeutic drugs have grown in complexity, so too have the bioanalysis techniques to support these products. Bioanalysis of small molecule
Share This
The LI-COR Odyssey Western blot delivers quantitative accuracy for target protein detection by using the platform’s infrared technology to match or exceed chemiluminescent detection sensitivity. Leveraging this platform’s capabilities, BioAgilytix is able to perform accurate, reproducible, quantitative Western blot assays.
LI-COR is an infrared (IR) laser-based instrumentation that is able to detect Western blots without the need for film, a darkroom, or any chemiluminescent substrates. Using infrared fluorescent signals that are directly proportional to the amount of target protein, LI-COR Odyssey can accurately and reproducibly measure changes in protein levels via ratiometric detection. In fact, the platform is able to detect both faint and strong bands within a single image, without signal saturation.
The LI-COR imager yields very low background fluorescence, which enables detection of low-picogram targets with NIR fluorescence, as well as low abundance proteins at endogenous levels. It also enables the detection of two targets simultaneously on the same membrane, which greatly increases accuracy of quantification and provides for more robust comparison.
Our passion for the science of small and large molecule bioanalysis drives our ability to deliver premium, tailored services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays.
The LI-COR platform has broad applicability for quantitative Western blots, protein gel imaging, and in-cell Westerns, providing for quantitative analysis and a wide linear dynamic range that is not available with traditional chemiluminescent methods. The accuracy and linearity of the system’s infrared detection provides for confident analysis of the differences in protein expression, and have made LI-COR the standard for quantitative Western blots compared to film.
In addition to two-color infrared and in-gel quantitative Western blots, BioAgilytix uses our LI-COR Odyssey platform for cell-based assays, protein detection, nucleic acid detection, protein arrays, RNAi analysis, and more.
The core benefits of the LI-COR Odyssey stem from its infrared fluorescence technology, which enables superior sensitivity, quantification, and linear range when compared to chemiluminescence and visible fluorescence detection. Its near-infrared detection generates low background fluorescence for a signal-to-noise ratio that is better than visible fluorescence, and equal to or greater than chemiluminescence. In fact, LI-COR is able to accurately detect both strong and weak signals in a single image over a 4-5 log linear dynamic range.
Another key advantage of the platform is its ability to multiplex two different targets on the same blot. Not only does this save time and precious sample volumes by multiplying data output, it makes normalization against an internal control for quantification more precise. This mitigates the potential errors that would be introduced from protein loss during stripping and re-probing, or by comparing blots separately. With its two-color detection and quantification, the LI-COR Odyssey can be used to analyze post-translational modifications of proteins, confirm protein identity, and more.
How do you decide which platform to go with in support of your project? Afshin Safavi, Ph.D., of BioAgilytix offers his expert opinion in this video.
When quantitative Western blot detection or near-infrared fluorescent imaging is needed, the BioAgilytix team knows the LI-COR platform will deliver the sensitivity and linearity required to yield accurate results. LI-COR removes the need for enzymatic reactions and substrates, with highly stable signals that generate high-quality data.
Let our experts show you how we can apply LI-COR’s robust detection capabilities to your next project.
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
+61 3 9282 2184
